EU Flagship Project Kick-Off: NVision Brings Together Partners to Advance Diagnostics and Treatment Monitoring with AI and HP-MRI

BRUSSELS, Belgium— NVision announced its key role in the Q-AID consortium, a new EU initiative focused on integrating quantum-enhanced metabolic imaging with advanced AI tools for medical diagnostics.The consortium will use POLARIS technology to address needs in cancer, Alzheimer's disease, and multiple sclerosis by supporting earlier diagnosis and treatment monitoring.This multi-year program, supported by the European Commission, focuses on preclinical validation and small-scale clinical studies (20–70 patients).
‍Learn more about Q-AID ↗

ULM, Germany - We joined the annual General Assembly of QuE-MRT, for a day focused on discussions and updates for advancing metabolic imaging.

This German flagship project is focused on building an end-to-end clinical platform for quantum-enhanced hyperpolarized metabolic MRI, including R&D work on the polarizer and MRI acquisition methods, preclinical research on cancer models, regulatory effort towards clinical studies in Germany and ultimately running clinical studies on 3 different cancer patient populations.

Once again, we were impressed by the progress happening on so many fronts:
- Standardized MRI acquisition protocols enabling broader adoption
- New, promising metabolic probes (like Z-OMPD and α-KIC)
- Key advances in the regulatory process toward the first clinical HP-MRI studies in Germany

Learn more about QuE-MRT ↗